A reversal of the usual approach

Part 1 described carrying a drug to a tumour in a pre-built particle. Chapter 8 of Peptide Nano-Chemistry and Nanotechnology describes a more ambitious idea: sending in small, harmless building blocks that only assemble into an active structure once they reach the cancer cell.

The logic is appealing. Small molecules get into cells more easily than large structures. And if assembly only happens in response to something specific to the cancer cell, the active structure forms mainly where it is wanted. The chapter describes this as achieving site-specific responsiveness within tumour regions, with reduced side effects.

The triggers inside a cancer cell

The chapter describes several internal triggers that differ between cancer cells and normal cells.

Acidity. The chapter notes the tumour microenvironment is slightly acidic (below pH 7), while normal tissue sits around 7.4.

Reactive oxygen species (ROS). Many cancer cells produce excess ROS, especially around their mitochondria.

Enzymes. Certain enzymes are overproduced in particular cancers.

Glutathione (GSH). The chapter describes GSH as overexpressed in many cancer cells. Glutathione is the cell's main antioxidant, and it can break disulfide bonds.

Each of these can be used as a switch.

Examples, trigger by trigger

pH switch. Researchers designed a pentapeptide (FF-Amp-FF) containing a modified proline whose bond flips shape depending on acidity. It reversibly switched between superhelices and nanoparticles as conditions alternated between neutral and mildly acidic. The chapter reports it accumulated better in tumours and improved drug delivery compared with nanomedicines that kept one fixed shape.

ROS switch. A polymer-peptide conjugate carried a mitochondria-targeting toxic peptide and a sheet-forming peptide, linked to PEG through a bond (thioketal) that ROS can cut. Near cancer cell mitochondria, the excess ROS cut the link, and the particles transformed into fibres that interacted strongly with mitochondria, killing the cells selectively.

Enzyme switches. Several examples:

  • Enterokinase, an enzyme near mitochondria, cut a tag off a peptide conjugate, triggering it to assemble and deliver a payload into the mitochondria of liver cancer cells.
  • Alkaline phosphatase removed a phosphate from a pyrene-peptide conjugate, which then assembled, lit up with a characteristic fluorescence, targeted lysosomes and damaged their membranes, killing cervical cancer cells.
  • Tyrosinase, an enzyme active in melanoma (it makes melanin), oxidised a simple tripeptide, FFY, into a melanin-like dimer that assembled into nanoparticles. These interfered with microtubules (the cell's internal scaffolding) and reversed drug resistance in melanoma.

That last example is especially neat: the tumour's own pigment-making machinery was used to build the weapon against it.

Glutathione plus enzyme. A molecule combining the cell-penetrating peptide RVRR with the drug olsalazine entered cells rich in an enzyme called furin. Inside, glutathione reduced it and furin cut it. The pieces then joined through a chemical reaction and assembled into nanoparticles of olsalazine, acting as a local drug reservoir that inhibited DNA methylation and also enhanced a type of MRI contrast.

Aiming at specific organelles

The chapter goes further, describing designs that target specific structures inside the cell:

  • Mitochondria, the cell's energy producers. The chapter notes malignant growth, invasion and spread are all linked to mitochondria. The Mito-FF peptide (a mitochondria-targeted diphenylalanine) accumulated in mitochondria, formed fibres once it reached a critical concentration, disrupted mitochondrial membranes, and triggered cell death.
  • Lysosomes, the cell's recycling compartments.
  • The endoplasmic reticulum, where proteins are folded.
  • The nucleus.

The chapter's conclusion argues that targeting organelles could reduce the dose needed and help overcome multidrug resistance.

The part worth thinking about

These designs are genuinely ingenious. But each relies on a difference between cancer and normal cells that is real but relative, not absolute.

Normal cells also contain glutathione, produce ROS, and express many of these enzymes. Liver cells in particular are rich in glutathione. Tumour acidity varies within a tumour and between patients. So "cancer cells have more of X" means the switch should flip more often in cancer cells, not only in cancer cells. Whether the difference is big enough to give a safe margin in a real patient is exactly what animal studies cannot fully answer.

The chapter's conclusion describes these strategies as having great potential for clinical application and says organelle targeting is expected to overcome multidrug resistance and completely eradicate tumours. That is the aspiration. The evidence described is in cells and mice.

Why this matters to you

Self-assembly inside cells is one of the most creative ideas in modern drug design. It turns the cancer cell's own chemistry against it, and it is a lovely example of how the self-assembly science from our first nanomaterials series could translate into medicine.

It is also a reminder of a principle worth applying to any health claim: when a treatment is described as "selective", ask how selective, and compared to what. Selectivity is almost always a matter of degree.

This series explains biomedical research for general readers. Most approaches described are at the laboratory or animal study stage and are not available treatments. Nothing here is medical advice. Anyone affected by cancer should rely on their oncology team.